Insights into SARS-CoV-2: Small-Molecule Hybrids for COVID-19 Treatment

Molecules. 2024 Nov 15;29(22):5403. doi: 10.3390/molecules29225403.

Abstract

The advantages of a treatment modality that combines two or more therapeutic agents with different mechanisms of action encourage the study of hybrid functional compounds for pharmacological applications. Molecular hybridization, resulting from a covalent combination of two or more pharmacophore units, has emerged as a promising approach to overcome several issues and has also been explored for the design of new drugs for COVID-19 treatment. In this review, we presented an overview of small-molecule hybrids from both natural products and synthetic sources reported in the literature to date with potential antiviral anti-SARS-CoV-2 activity.

Keywords: COVID-19; SARS-CoV-2 Mpro; antiviral activity; drug design; molecular hybridization; natural product hybrids; small molecules.

Publication types

  • Review

MeSH terms

  • Antiviral Agents* / chemistry
  • Antiviral Agents* / pharmacology
  • Antiviral Agents* / therapeutic use
  • Biological Products / chemistry
  • Biological Products / pharmacology
  • Biological Products / therapeutic use
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Humans
  • SARS-CoV-2* / drug effects
  • Small Molecule Libraries / chemistry
  • Small Molecule Libraries / pharmacology

Substances

  • Antiviral Agents
  • Biological Products
  • Small Molecule Libraries

Grants and funding

This research received no external funding.